Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BCL6
REST API REST API
Homo sapiens
BCL6 is differentially expressed in 368 experiments: 138 organism parts: cerebellum, kidney, ... (136 more);, 234 disease states: normal, Burkitt's lymphoma, ... (232 more);, 128 cell types 411 cell lines 80 compound treatments and 81 other conditions.
Synonyms LAZ3, ZNF51, BCL5, BCL6A, ZBTB27
Orthologs BCL6 (Gallus gallus)   bcl6ab (Danio rerio)   bcl6a (Danio rerio)   Bcl6 (Mus musculus)   BCL6 (Bos taurus)   Q4H3U8_CIOIN (Ciona intestinalis)   Bcl6 (Rattus norvegicus)   bcl6 (Xenopus laevis)   BCL6 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term negative regulation of S phase of mitotic cell cycle, negative regulation of cell growth, DNA binding, protein localization, negative regulation of transcription, DNA-dependent, protein binding, regulation of cell proliferation, intracellular, negative regulation of cell proliferation, transcription, DNA-dependent, protein import into nucleus, translocation, negative regulation of apoptosis, replication fork, metal ion binding, nucleic acid binding, spermatogenesis, cell morphogenesis, Rho protein signal transduction, positive regulation of apoptosis, sequence-specific DNA binding, actin cytoskeleton organization, nucleus, chromatin DNA binding, chromatin binding, negative regulation of transcription from RNA polymerase II promoter, response to DNA damage stimulus, negative regulation of cell differentiation, regulation of immune response, zinc ion binding, germinal center formation, negative regulation of Rho protein signal transduction, B cell differentiation, positive regulation of B cell proliferation, erythrocyte development, regulation of Rho GTPase activity, regulation of memory T cell differentiation, negative regulation of mast cell cytokine production, regulation of inflammatory response, negative regulation of cell-matrix adhesion, negative regulation of isotype switching to IgE isotypes, positive regulation of cellular component movement, negative regulation of T-helper 2 cell differentiation, negative regulation of B cell apoptosis, sequence-specific DNA binding transcription factor activity, regulation of germinal center formation, type 2 immune response, negative regulation of type 2 immune response
InterPro Term Znf_C2H2-like, BTB_POZ, BTB/POZ-like, Znf_C2H2
UniProt Accession B8PSA7, P41182, C9JCS5, C9JL16
Search EB-eye ENSG00000113916
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (40 experiments)

Factor Value U/D Experiments
K562
3
E-MTAB-37, E-GEOD-24147, E-GEOD-96
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
H441
2
E-GEOD-16194, E-MTAB-62
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MDA468
2
E-MEXP-440, E-MTAB-62
405 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (59 experiments)

Factor Value U/D Experiments
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
centroblast
2
E-TABM-702, E-GEOD-15271
fibroblast
2
E-GEOD-3920, E-GEOD-3204
monocyte
2
3
E-MEXP-583, E-GEOD-22373, E-GEOD-11755, E-GEOD-8286, E-MEXP-2019 ... (5 experiments)
CD4+ T cell
2
3
E-GEOD-16190, E-MTAB-24, E-AFMX-5, E-MTAB-25, E-MEXP-1600 ... (5 experiments)
122 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-TABM-15, ... (76 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-995, E-MTAB-62, E-GEOD-96
breast cancer
2
E-GEOD-22544, E-MTAB-62
control
2
E-GEOD-21912, E-GEOD-8121
glioblastoma
2
E-GEOD-4290, E-MTAB-37
lymphoma
2
E-MTAB-37, E-MTAB-62
neuroblastoma
2
E-MTAB-62, E-MTAB-37
228 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-697, ... (42 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-3720
sapphyrin PCI-2055
1
E-GEOD-6400
TGF-Beta1
1
E-MEXP-2645
baseline sevoflurane
1
E-GEOD-4386
propofol
1
E-GEOD-4386
AMP
1
E-MEXP-2285
74 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, E-GEOD-3140, ... (11 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, ... (18 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-GEOD-5764, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (39 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-6802, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-2634, E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-2487, ... (6 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-19330, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, ... (6 experiments)

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19136, E-GEOD-13818, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922

Processing time: 0.39 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM